CELC significantly increased cash position to $165.7M (+636%) but dramatically worsened operating performance with net losses expanding to -$177.0M (-58.4%) and operating cash burn accelerating to -$153.3M (-83.6%).
The massive cash increase suggests CELC completed a major financing round, which is positive for near-term liquidity but came at the cost of substantial dilution (shares outstanding increased 28% to 48.3M). The deteriorating operational metrics indicate accelerating cash burn as the company advances its Phase 3 gedatolisib trials, creating pressure to achieve clinical milestones before requiring additional financing.
CELC's financial profile shows a company that secured significant capital but is burning through it rapidly. While cash and equivalents surged 636% to $165.7M and total assets nearly doubled, the company's net losses widened 58% to -$177M with operating cash outflows worsening 84% to -$153M. The 39% increase in R&D expenses to $145M and 153% jump in interest expense to $5.3M reflect both accelerated clinical trial activity and higher debt costs, suggesting CELC is in a critical phase where clinical trial success will determine whether the current cash runway provides sufficient time to reach value-creating milestones.
Cash position surged 636% — strong cash generation or capital raise providing significant financial cushion.
Liabilities grew 182.6% — significant increase in debt or obligations, assess impact on financial flexibility.
Interest expense surged 152.9% — significant debt increase or rising rates materially impacting earnings.
Current assets grew 90.4% — improving short-term liquidity or inventory/receivables build.
Asset base grew 90.3% — expansion through organic growth, acquisitions, or capital deployment.
Operating cash flow fell 83.6% — earnings quality concerns; investigate working capital changes and non-cash items.
Net income declined 58.4% — review whether driven by operations, interest costs, or non-recurring items.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Current liabilities surged 39.2% — significant near-term obligations; verify ability to meet short-term debt.
R&D investment increased 39.1% — signals commitment to future product development, though near-term margin impact.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →